The Biotechmed Forum was held in Sochi on the 19-20 of September, where representatives of federal executive authorities and leading companies in the industry annually discuss key issues in the development of biomedical technologies in the country.
Ensuring national independence in the implementation of vital healthcare tasks was the main theme of the Forum in 2022. At the plenary session “Strategic Initiatives in Healthcare”, the Deputy Prime Minister of the Russian Federation - Minister of Industry and Trade of the Russian Federation Denis Manturov emphasized that, despite the introduction of a number of indirect restrictions in the current geopolitical situation, the pharmaceutical and medical industries have managed to respond to all challenges with quality and speed.
The main priority of the state and business remains the uninterrupted provision of citizens with the necessary medicines and medical devices.
Denis Manturov noted that the industry has quickly established new cooperation links within the country and expanded cooperation with partners from friendly countries, which allows the industry to remain sustainable in the current situation.
During the previous 7 months, domestic pharmaceutical manufacturers registered over 740 pharmaceutical products in various forms, which was 80% of the total number of issued registration certificates. The number of clinical trials conducted by Russian pharmaceutical companies has also increased against the background of reduced activity by foreign manufacturers in this area.
Each Forum section included topics on state support measures available to the pharmaceutical and medical device industry. Vasily Osmakov, Deputy Minister of Industry and Trade of the Russian Federation, stated that the pharmaceutical sector is one of the most protected amid complex supply chains and sanctions policies.
Mikhail Murashko, Minister of Health of Russia, noted the important role of the introduced medicines labelling system in preventing pharmaceutical products shortages and forecasting the need for them. The COVID-19 pandemic was also a powerful catalyst for the domestic pharmaceutical industry development: most of the medicines used in the domestic healthcare system to treat and prevent coronavirus infection were produced in Russia. The manufacturing of innovative medicines, new materials and medical products must be developed and localized, and the entire cycle must be present in the country in the form of scientific and production competencies. At the same time, Mikhail Murashko reminded that it is necessary to create conditions for the rapid launch of new medicines on the market without compromising safety and effectiveness.
An important emphasis of the event is placed on the need to develop the chemical industry, as the creation of full-cycle production implies import-independence of the raw material base in terms of intermediates and reagents.
Biotechmed Forum is a unique platform that brings together representatives of government, industry, science and education of the pharmaceutical industry. The event format creates the conditions for constructive meetings and the establishment of business relations.
Mikhail Fonarev, General Director of FSUE Endopharm, took an active part in the sections of the Forum's business program, where he shared with industry representatives the practical aspects of organizing the work of a pharmaceutical company in the current geopolitical situation. FSUE Endopharm presented at the Biotechmed Forum a project implemented jointly with the Russian Ministry of Industry and Trade on cultivation of plant raw materials for manufacturing of socially important pharmaceutical substances at the ENDOPHARM Agro Branch.
A modern high-tech complex comprising the agricultural division of FSUE Endopharm and the Pochep branch located in the Bryansk Region with an annual production capacity of over 30 tons of substances, as well as two sites for manufacturing finished dosage forms located in Moscow, by 2025 will ensure the drug safety of the country for a number of vital and socially important medicines through their full-cycle production, including full localization of opiate production in the Russian Federation
Comment type is not specified in the component properties.